Recombinant antibodies have become the most rapidly expanding class of human therapeutics. Our research is focused on the discovery, design, engineering and production of novel antibody-based therapeutics for immunotherapy of malignant tumors and viral diseases. The group employs technologies for generating humanized and fully human antibodies and has unique expertise in engineering tumor-targeting antibodies with properties that are essential to their successful clinical translation (i.e. low immunogenicity, specificity, high affinity, and biophysical stability).
Prof. Dr. med. Jürgen Krauss
Head of research group "Antibody- and Cell-based Immunotherapeutics"
Head of division "Immunotherapy"